Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 1, 2012, Pages 67-76

  Richards, Thomas J ^a   Kaminski, Naftali ^a   Baribaud, Fred ^b   Flavin, Susan ^b   Brodmerkel, Carrie ^b   Horowitz, Daniel ^b   Li, Katherine ^b   Choi, Jiin ^a   Vuga, Louis J ^a   Lindell, Kathleen O ^a   Klesen, Melinda ^a   Zhang, Yingze ^a   Gibson, Kevin F ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Adhesion molecules; Biomarkers; MMP 7; Mortality prediction; Personalized medicine

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRILYSIN; PLASMA PROTEIN; PROTEIN S 100; S100A12 PROTEIN; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; S100 PROTEINS; SURVIVAL ANALYSIS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84855264195     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201101-0058OC     Document Type: Article

References (66)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
2. Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 2005;128:526S-532S.
3. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151. (Pubitemid 32096342)
4. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:1321-1332. (Pubitemid 40586504)
5. Yogo Y, Fujishima S, Inoue T, Saito F, Shiomi T, Yamaguchi K, Ishizaka A. Macrophage derived chemokine (CCL22), thymus and activationregulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respir Res 2009;10:80.
6. Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Matsuba T, Yoshimi M, Inoshima I, Yoshida K, Hara N. Upregulation of fassignalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J 2001;17:180-189. (Pubitemid 32600575)
7. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008;5:e62.
8. Kliment CR, Oury TD. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 2010;49:707-717.
9. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010;65:537-553.
10. Strieter RM, Belperio JA, Keane MP. CXC chemokines in vascular remodeling related to pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:S67-S69. (Pubitemid 37070312)
11. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-967.
12. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Perez-Padilla R, Navarro C, Richards T, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007;2:e482.
13. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137:129-137.
14. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;183:431-440.
15. Bargagli E, Olivieri C, Bennett D, Prasse A, Muller-Quernheim J, Rottoli P. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009;103:1245-1256.
16. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, Bando M, Sugiyama Y, Totani Y, Ishizaki T, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11:164-168. (Pubitemid 43356896)
17. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Muller-Quernheim J. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:717-723.
18. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009;135:1557-1563.
19. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
20. Richards TJ, Lindell KO, Klesen M, Kaminski N, Zhang Y, Gibson K. Peripheral blood biomarkers predict disease progression and mortality in IPF. Am J Respir Crit Care Med 2010;181:A1120.
21. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 2002;19:794-796. (Pubitemid 34567889)
22. Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA III, Sporn TA, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-1152. (Pubitemid 43066651)
23. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-1181. (Pubitemid 33052246)
24. Bouwman FG, de Roos B, Rubio-Aliaga I, Crosley LK, Duthie SJ, Mayer C, Horgan G, Polley AC, Heim C, Coort SL, et al. 2D-electrophoresis and multiplex immunoassay proteomic analysis of different body fluids and cellular components reveal known and novel markers for extended fasting. BMC Med Genomics 2011;4:24.
25. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
26. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graph Statist 1996;5:299-314.
27. Murphy SA, van der Vaart AW. On profile likelihood. J Am Stat Assoc 2000;95:449-485.
28. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-969. (Pubitemid 36408161)
29. Venables WN, Ripley BD. Modern applied statistics with S, 4th ed. New York: Springer; 2002.
30. du Bois RM,Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-466.
31. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL III, Paine R, Flint A, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-283. (Pubitemid 34162828)
32. King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-1032. (Pubitemid 32971653)
33. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-2217. (Pubitemid 32051689)
34. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Harvard University Biostatistics Working Paper Series 2009:101.
35. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-344. (Pubitemid 30422619)
36. Prasse A, Muller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009;14:788-795.
37. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-6297. (Pubitemid 34493305)
38. Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, Nakamura M, Tasaka S, Hasegawa N, Aikawa N, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med 2010;134:1136-1142.
39. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et al. Aberrant WNT/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-1502. (Pubitemid 36512831)
40. Konigshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W, Eickelberg O. Functional WNT signaling is increased in idiopathic pulmonary fibrosis. PLoS ONE 2008;3:e2142.
41. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009;119:772-787.
42. Vuga LJ, Ben-Yehudah A, Kovkarova-Naumovski E, Oriss T, Gibson KF, Feghali-Bostwick C, Kaminski N. WNT5a is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol 2009;41:583-589.
43. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002;111:635-646. (Pubitemid 35441246)
44. McGuire JK, Li Q, Parks WC. Matrilysin (matrix metalloproteinase-7) mediates e-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 2003;162:1831-1843. (Pubitemid 36613042)
45. Swee M, Wilson CL, Wang Y, McGuire JK, Parks WC. Matrix metalloproteinase-7 (matrilysin) controls neutrophil egress by generating chemokine gradients. J Leukoc Biol 2008;83:1404-1412. (Pubitemid 351960321)
46. Wilson CL, Schmidt AP, Pirila E, Valore EV, Ferri N, Sorsa T, Ganz T, Parks WC. Differential processing of {alpha}- and {beta}-defensin precursors by matrix metalloproteinase-7 (MMP-7). J Biol Chem 2009;284:8301-8311.
47. Griffith B, Pendyala S, Hecker L, Lee PJ, Natarajan V, Thannickal VJ. Nox enzymes and pulmonary disease. Antioxid Redox Signal 2009;11:2505-2516.
48. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. Nadph oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-1081.
49. Epperly MW, Sikora CA, DeFilippi SJ, Gretton JE, Bar-Sagi D, Archer H, Carlos T, Guo H, Greenberger JS. Pulmonary irradiation-induced expression of VCAM-1 and ICAM-1 is decreased by manganese superoxide dismutase-plasmid/ liposome (MNSOD-PL) gene therapy. Biol Blood Marrow Transplant 2002;8:175-187. (Pubitemid 34520532)
50. Epperly MW, Guo H, Shields D, Zhang X, Greenberger JS. Correlation of ionizing irradiation-induced late pulmonary fibrosis with long-term bone marrow culture fibroblast progenitor cell biology in mice homozygous deletion recombinant negative for endothelial cell adhesion molecules. In Vivo 2004;18:1-14. (Pubitemid 38263365)
51. Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. Lung function in idiopathic pulmonary fibrosis: extended analyses of the IFIGENIA trial. Respir Res 2009;10:101.
52. Radomska-Lesniewska DM, Skopinska-Rozewska E, Jankowska-Steifer E, Sobiecka M, Sadowska AM, Hevelke A, Malejczyk J. N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung disease patients. Pharmacol Rep 2010;62:131-138.
53. Radomska-Lesniewska DM, Sadowska AM, Van Overveld FJ, Demkow U, Zielinski J, De Backer WA. Influence of N-acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J Physiol Pharmacol 2006;57:325-334. (Pubitemid 44638216)
54. Sadowska AM, Manuel-y-Keenoy B, Vertongen T, Schippers G, Radomska-Lesniewska D, Heytens E, De Backer WA. Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: in vivo and in vitro study. Pharmacol Res 2006;53:216-225. (Pubitemid 43250662)
55. Sato N, Suzuki Y, Nishio K, Suzuki K, Naoki K, Takeshita K, Kudo H, Miyao N, Tsumura H, Serizawa H, et al. Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycininduced fibrotic lung injury. Am J Respir Crit Care Med 2000;161:1681-1688. (Pubitemid 30329048)
56. Takehara H, Tada S, Kataoka M, Matsuo K, Ueno Y, Ozaki S, Miyake T, Fujimori Y, Yamadori I, Harada M. Intercellular adhesion molecule-1 in patients with idiopathic interstitial pneumonia. Acta Med Okayama 2001;55:205-211. (Pubitemid 33605254)
57. Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K, Takehara K. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 1997;36:1270-1275.
58. Nakao A, Hasegawa Y, Tsuchiya Y, Shimokata K. Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis. Chest 1995;108:233-239.
59. Fichtner F, Koslowski R, Augstein A, Hempel U, Rohlecke C, Kasper M. Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells. Exp Toxicol Pathol 2004;55:497-503. (Pubitemid 39090337)
60. Carre PC, Mortenson RL, King TE Jr, Noble PW, Sable CL, Riches DW. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 1991;88:1802-1810.
61. Xaubet A, Agusti C, Luburich P, Barbera JA, Carrion M, Ayuso MC, Roca J, Rodriguez-Roisin R. Interleukin-8 expression in bronchoalveolar lavage cells in the evaluation of alveolitis in idiopathic pulmonary fibrosis. Respir Med 1998;92:338-344. (Pubitemid 28116262)
62. Kikkawa T, Sato N, Kojika M, Takahashi G, Aoki K, Hoshikawa K, Akitomi S, Shozushima T, Suzuki K, Wakabayashi G, et al. Significance of measuring S100A12 and SRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg 2010;27:307-312.
63. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167-175.
64. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE Jr, Matthay MA, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010;299:L3-L7.
65. Raghu G. Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur Respir J 2006;28:463-465. (Pubitemid 44794656)
66. Wells AU, Richards TJ, Martinez FJ. Baseline values and short serial change. A "road map" for a poor early outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:395-397.